Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7455
Reference
MSAN(2021)33
Name
Champix® (varenicline) 0.5mg and 1mg tablets
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
1. There is no date for resupply of Champix® (varenicline) or availability of varenicline products until further notice. 2. The Medicines and Healthcare products Regulatory Agency (MHRA) initiated a class 2 medicines recall (EL 21 A/25) of all strengths of Champix® tablets (all in-date batches) on 14th October 2021 at pharmacy and wholesaler level. 3. There are currently no alternative suppliers of varenicline tablets. 4. Patients currently prescribed this treatment will require review and switching to nicotine replacement therapy (NRT) unless contraindicated. 5. No new patients should be initiated on Champix® (varenicline) products. 6. Prescribers initiating smoking cessation treatment for new patients should consider prescribing NRT or bupropion 150mg prolonged release tablets unless contraindicated. 7. Helping a patient to stop smoking should not be delayed if they are motivated to stop as other effective options are available.
Contact Name
Contact Email
Contact Address
Created
2021-11-09 00:00:00
Click to go back to homepage